Drug treatment of secondary schizophrenia

Jibson, Michael D.; Tandon, Rajiv

doi:10.1017/cbo9780511789977.033

Cited by 2 publications

(2 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These different degrees of separation are of particular relevance in vulnerable patient populations and as the dosage of the "atypical" antipsychotic agent is increased. Whereas clozapine and quetiapine are not associated with any dose-dependent increase in risk of EPS across their entire dose range (5), olanzapine and ziprasidone can be associated with EPS (particularly akathisia) at their higher doses (4,43), and risperidone is associated with a clear dose-dependent increase in risk of EPS (3). Regardless, when one uses any of the newer generation of "atypical" antipsychotics, it is crucial to recognize that the principal factor contributing to their multiple advantages over the older conventional agents is their lower liability of EPS.…”

Section: What Do the Newer "Atypical Antipsychotics" Offer?mentioning

confidence: 99%

Extrapyramidal Side Effects of Antipsychotic Treatment: Scope of Problem and Impact on Outcome

Tandon¹,

Jibson²

2002

Ann. of Clinical Psychiatry

Self Cite

View full text Add to dashboard Cite

Previously, clinicians worked with antipsychotic drugs (conventional or typical) that almost invariably caused extrapyramidal symptoms (EPS) at clinically effective doses. This led to the false impression that all antipsychotics were the same, and that EPS were an unavoidable consequence of effective antipsychotic therapy. EPS adversely impact several aspects of antipsychotic efficacy and tolerability, thereby worsening outcome of afflicted individuals. EPS reduce beneficial effects of antipsychotic treatment on the negative, cognitive, and mood symptom domains, while increasing the risk of tardive dyskinesia and reducing compliance. By definition, the newer generation of "atypical" antipsychotic agents are significantly better than conventional agents with regard to EPS (i.e., they are clinically effective at doses at which they do not cause EPS). Pharmacologically, this difference is expressed in the greater degree of separation between respective dose response curves for antipsychotic and EPS effects observed for "atypical" in contrast to conventional agents. Clinically, this EPS advantage of atypical antipsychotics translates into several important benefits, including better negative symptom efficacy, less dysphoria, less impaired cognition, a lower risk of TD, and better overall outcome.

show abstract

Section: What Do the Newer "Atypical Antipsychotics" Offer?mentioning

confidence: 99%

Extrapyramidal Side Effects of Antipsychotic Treatment: Scope of Problem and Impact on Outcome

Tandon¹,

Jibson²

2002

Ann. of Clinical Psychiatry

Self Cite

View full text Add to dashboard Cite

show abstract

“…Furthermore, no significant differences between SGA and "typical" antipsychotics in terms of the rate of suicide or suicide attempts were demonstrated in phase III studies of risperidone, olanzapine, and quetiapine submitted to the Food and Drug Administration in the US (Khan et al 2001). However, several other reports (Keck et al 2000;Peuskens et al 2000;Aleman and Kahn 2001) document the utility of all "atypical" antipsychotics in reducing suicidality in schizophrenia, although important differences between these agents are identified as well (Jibson and Tandon 2000;Chakos et al 2001).…”

Section: Introductionmentioning

confidence: 99%